Brought to you by 
Molecular Partners brings in CHF46mm via its Series B round
15 Dec 2009
Executive Summary
Molecular Partners AG (developing next-generation protein therapeutics) has raised CHF46mm ($45mm) through the closing of its Series B venture round. New investor Essex Woodlands Health Ventures led (and contributes a board member) and was joined by current backers Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures, and Endeavour.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Molecular Partners brings in CHF46mm via its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice